NCT04380194View on ClinicalTrials.gov

Intracorporeal Nanocomposites and Neurological Disorders in Fulgurates (FulgurnanoF)

CompletedOBSERVATIONAL
Enrollment

27

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

September 10, 2020

Study Completion Date

September 10, 2020

Conditions
Neurologic Disorder
Interventions
DIAGNOSTIC_TEST

nano-composite screening

Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses

Trial Locations (5)

Unknown

CH Henri Mondor, Aurillac

CH de Luneville, Lunéville

CHRU Bradois, Nancy

CHRU de Nancy, Nancy

CH de SAINT-DIE-DES-VOSGES, Saint-Dié

All Listed Sponsors
collaborator

PROMES UPR 8521 DR2-CNRS

UNKNOWN

collaborator

LPC UMR 6533, Campus Universitaire des Cézeaux

UNKNOWN

lead

University Hospital, Clermont-Ferrand

OTHER

NCT04380194 - Intracorporeal Nanocomposites and Neurological Disorders in Fulgurates (FulgurnanoF) | Biotech Hunter | Biotech Hunter